MA39082A1 - Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet - Google Patents
Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujetInfo
- Publication number
- MA39082A1 MA39082A1 MA39082A MA39082A MA39082A1 MA 39082 A1 MA39082 A1 MA 39082A1 MA 39082 A MA39082 A MA 39082A MA 39082 A MA39082 A MA 39082A MA 39082 A1 MA39082 A1 MA 39082A1
- Authority
- MA
- Morocco
- Prior art keywords
- polynucleotide
- interest
- retinal pigment
- subject
- pigment epithelium
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Marine Sciences & Fisheries (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
Abstract
L'invention concerne des méthodes et des compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet. L'invention concerne, en particulier, une méthode pour exprimer sélectivement un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien dans l'œil d'un sujet qui en a besoin, comprenant l'étape consistant à transduire l'épithélium pigmentaire rétinien avec une quantité de vecteur raav2/5 contenant le polynucléotide d'intérêt.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP13306676 | 2013-12-06 | ||
PCT/EP2014/076740 WO2015082690A1 (fr) | 2013-12-06 | 2014-12-05 | Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet |
Publications (2)
Publication Number | Publication Date |
---|---|
MA39082A1 true MA39082A1 (fr) | 2017-10-31 |
MA39082B2 MA39082B2 (fr) | 2021-11-30 |
Family
ID=49885103
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA39082A MA39082B2 (fr) | 2013-12-06 | 2014-12-05 | Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet |
Country Status (14)
Country | Link |
---|---|
US (1) | US10105452B2 (fr) |
EP (1) | EP3077520A1 (fr) |
JP (2) | JP6875856B2 (fr) |
KR (1) | KR102281881B1 (fr) |
CN (1) | CN105940109A (fr) |
AU (1) | AU2014359136B2 (fr) |
BR (1) | BR112016012716A2 (fr) |
CA (1) | CA2932495A1 (fr) |
IL (1) | IL245989A0 (fr) |
MA (1) | MA39082B2 (fr) |
MX (1) | MX2016007278A (fr) |
RU (1) | RU2723101C2 (fr) |
TN (1) | TN2016000220A1 (fr) |
WO (1) | WO2015082690A1 (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201604146D0 (en) * | 2016-03-10 | 2016-04-27 | Nightstarx Ltd | Prenylation assay |
CN107287238B (zh) * | 2016-04-11 | 2020-10-16 | 厦门继景生物技术有限责任公司 | 一种基因载体及其用于治疗雷柏氏先天性黑矇2型疾病的基因治疗药物 |
CA3025977A1 (fr) | 2016-10-11 | 2018-04-19 | Wellstat Ophthalmics Corporation | Proteine de fusion entre un facteur de viabilite de cone derive d'une tige courte et un peptide hydrophile |
WO2018085844A1 (fr) * | 2016-11-07 | 2018-05-11 | Spark Therapeutics, Inc. | Dosage d'activité de protéine d'escorte de rab |
US20200255859A1 (en) * | 2017-07-31 | 2020-08-13 | Reflection Biotechnologies Limited | Cellular models of and therapies for ocular diseases |
AU2018350990A1 (en) * | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Treatment of ocular diseases and metastatic colon cancer with human post-translationally modified VEGF-Trap |
SG11202009759SA (en) * | 2018-04-05 | 2020-10-29 | Univ Oxford Innovation Ltd | Compositions and methods for treating macular dystrophy |
CN109136266B (zh) * | 2018-08-10 | 2022-02-18 | 深圳泓熙生物科技发展有限公司 | 用于治疗或预防结晶样视网膜色素变性的基因载体及其用途 |
CN109112134B (zh) * | 2018-09-28 | 2020-06-02 | 中国人民解放军陆军军医大学第一附属医院 | 一种视网膜变性疾病的best1新突变致病基因及其试剂盒 |
RU2732479C2 (ru) * | 2018-12-21 | 2020-09-17 | Селл энд Джин Терапи Лтд | Генотерапевтический ДНК-вектор на основе генотерапевтического ДНК-вектора VTvaf17, несущий целевой ген, выбранный из группы генов BDNF, VEGFA, BFGF, NGF, GDNF, NT3, CNTF, IGF1, для повышения уровня экспрессии этих целевых генов, способ его получения и применения, штамм Escherichia coli SCS110-AF/VTvaf17-BDNF, или Escherichia coli SCS110-AF/VTvaf17-VEGFA, или Escherichia coli SCS110-AF/VTvaf17-BFGF, или Escherichia coli SCS110-AF/VTvaf17-NGF, или Escherichia coli SCS110-AF/VTvaf17-GDNF, или Escherichia coli SCS110-AF/VTvaf17-NT3, или Escherichia coli SCS110-AF/VTvaf17-CNTF, или Escherichia coli SCS110-AF/VTvaf17-IGF1, несущий генотерапевтический ДНК-вектор, способ его получения, способ производства в промышленных масштабах генотерапевтического ДНК-вектора |
CN113795279A (zh) * | 2019-03-04 | 2021-12-14 | 宾夕法尼亚州大学信托人 | 靶向akt通路的神经保护性基因疗法 |
CN110455655B (zh) * | 2019-08-23 | 2024-05-28 | 水利部杭州机械设计研究所 | 一种热喷涂涂层高通量检测装置及测试方法 |
CN110791502B (zh) * | 2019-12-04 | 2022-07-08 | 陕西理工大学 | 人源rbp4启动子片段及其应用 |
CN113952472A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
WO2023213817A1 (fr) * | 2022-05-02 | 2023-11-09 | Fondazione Telethon Ets | Thérapie génique pour l'atrophie gyrate de la choroïde et de la rétine |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103849629B (zh) * | 2006-06-21 | 2017-06-09 | 尤尼克尔Ip股份有限公司 | 具有经修饰的用于在昆虫细胞中产生aav的aav‑rep78翻译起始密码子的载体 |
CN101980668A (zh) * | 2008-02-07 | 2011-02-23 | 赛拉基因公司 | 通过玻璃体内施用编码治疗用蛋白质的表达载体救援光感器 |
US20120172419A1 (en) * | 2009-09-15 | 2012-07-05 | Medical College Of Wisconsin Research Foundation Inc. | Reagents and methods for modulating cone photoreceptor activity |
EP3156062A1 (fr) | 2010-05-17 | 2017-04-19 | Sangamo BioSciences, Inc. | Nouvelles protéines à liaison adn et leurs utilisations |
GB201103062D0 (en) * | 2011-02-22 | 2011-04-06 | Isis Innovation | Method |
-
2014
- 2014-12-05 TN TN2016000220A patent/TN2016000220A1/en unknown
- 2014-12-05 MX MX2016007278A patent/MX2016007278A/es unknown
- 2014-12-05 WO PCT/EP2014/076740 patent/WO2015082690A1/fr active Application Filing
- 2014-12-05 CA CA2932495A patent/CA2932495A1/fr not_active Abandoned
- 2014-12-05 RU RU2016127246A patent/RU2723101C2/ru active
- 2014-12-05 AU AU2014359136A patent/AU2014359136B2/en not_active Ceased
- 2014-12-05 KR KR1020167018183A patent/KR102281881B1/ko active IP Right Grant
- 2014-12-05 US US15/101,591 patent/US10105452B2/en active Active
- 2014-12-05 MA MA39082A patent/MA39082B2/fr unknown
- 2014-12-05 JP JP2016557191A patent/JP6875856B2/ja active Active
- 2014-12-05 BR BR112016012716-1A patent/BR112016012716A2/pt not_active IP Right Cessation
- 2014-12-05 CN CN201480074447.1A patent/CN105940109A/zh active Pending
- 2014-12-05 EP EP14830801.8A patent/EP3077520A1/fr not_active Ceased
-
2016
- 2016-06-02 IL IL245989A patent/IL245989A0/en unknown
-
2019
- 2019-10-25 JP JP2019194672A patent/JP2020023568A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
US10105452B2 (en) | 2018-10-23 |
JP6875856B2 (ja) | 2021-05-26 |
KR102281881B1 (ko) | 2021-07-27 |
TN2016000220A1 (en) | 2017-10-06 |
CN105940109A (zh) | 2016-09-14 |
US20160310618A1 (en) | 2016-10-27 |
CA2932495A1 (fr) | 2015-06-11 |
JP2020023568A (ja) | 2020-02-13 |
MA39082B2 (fr) | 2021-11-30 |
AU2014359136A1 (en) | 2016-06-16 |
IL245989A0 (en) | 2016-07-31 |
BR112016012716A2 (pt) | 2020-11-24 |
JP2017500060A (ja) | 2017-01-05 |
MX2016007278A (es) | 2016-09-16 |
RU2723101C2 (ru) | 2020-06-08 |
AU2014359136B2 (en) | 2020-06-25 |
KR20170009812A (ko) | 2017-01-25 |
EP3077520A1 (fr) | 2016-10-12 |
WO2015082690A1 (fr) | 2015-06-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39082A1 (fr) | Méthodes et compositions pharmaceutiques pour exprimer un polynucléotide d'intérêt dans l'épithélium pigmentaire rétinien d'un sujet | |
EP4393495A3 (fr) | Compositions d'arni de ligand 1 de mort cellulaire programmée 1 (pd-l1) et leurs procédés d'utilisation | |
SG10201903823QA (en) | Methods and compositions relating to microbial treatment and diagnosis of disorders | |
WO2017019660A8 (fr) | Compositions d'arni de xanthine déshydrogénase et leurs méthodes d'utilisation | |
WO2016130806A3 (fr) | Compositions d'arni du gène codant pour la protéine 3 contenant un domaine phospholipase de type patatine (pnpla3) et leurs procédés d'utilisation | |
MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
PH12019550076A1 (en) | SERPINA1 iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
MA43347A (fr) | Compositions et méthodes permettant d'inhiber l'expression du gène de lpa | |
WO2015179724A8 (fr) | Compositions d'arni produisant un effet sur l'angiotensinogène (agt) et leurs procédés d'utilisation | |
MA38261A1 (fr) | Composes comprenant un noyau polycyclique destines a etre utilises dans le traitement de l'hepatite c (vhc) | |
WO2014190157A8 (fr) | Compositions de tmprss6 et méthodes d'utilisation de ces compositions | |
MX2016007492A (es) | Métodos y composiciones para el tratamiento de afecciones asociadas con el envejecimiento. | |
MX2015009552A (es) | Composiciones que incluyen agentes para conferir caracter hidrofobico y estabilizantes y metodos para elaborar y usar los mismos. | |
MA38174A1 (fr) | Souche de bifidobacterium animalis ssp. Animalis | |
ZA201801868B (en) | Oil-based suspension concentrates with low gravitational separation and low viscosity | |
IL251866A0 (en) | Identifying an individual's abilities, skills and interests through game data analysis | |
BR112017004613A2 (pt) | processo para a preparação de 3-(3-cloro-1h-pirazol-1-il)piridina | |
PH12016501902B1 (en) | Composition in the form of an oil-in-water emulsion comprising ground white or yellow mustard seed | |
MX2017009103A (es) | Metodo y aparato para evaluar la eficacia del tratamiento de la sensibilidad dental con un producto para el cuidado bucal. | |
MA39462A1 (fr) | Nouvel activateur de sol contenant du lignosulfonate d'ammonium, et ses utilisations | |
Shin | The effects of hospital accreditation program to the organizational culture, job satisfaction, financial performances and patient safety at geriatric hospital: about Busan metrocity | |
PH12016501901A1 (en) | Composition in the form of an oil-in-water emulsion comprising ground white or yellow mustard seed | |
MX2016015597A (es) | Composicion detergente mejorada. | |
Hua et al. | The relationship between Internet addiction and life events of college students: The mediating effect of escape motivation | |
IN2015MN00091A (fr) |